The move marks a significant step in the company’s strategy to build a sustainable and direct commercial presence in the US, allowing it to oversee brand strategy, market access and customer engagement for the product.
RYALTRIS®, a nasal spray combining olopatadine hydrochloride and mometasone furoate, is approved by the US Food and Drug Administration for the treatment of symptoms associated with seasonal allergic rhinitis in adults and paediatric patients aged 12 years and above. The formulation combines an antihistamine and a corticosteroid in a single treatment option designed to help manage allergy symptoms.
The product was launched in the United States in 2022 and has since been introduced across several global markets. According to the company, RYALTRIS® is already approved in key regions including the United States, the European Union, the United Kingdom, Australia, South Korea, Russia and China. During FY26, the treatment was also rolled out in 11 additional markets, taking its overall presence to 55 countries worldwide.
Glenmark said taking direct control of commercialisation would enable closer alignment with healthcare providers and improved responsiveness to market requirements while strengthening its long-term innovation-driven growth strategy in the US.
Also read: Glenmark Pharma launches Potassium Phosphates Injection in US market
The company also noted that seasonal allergic rhinitis affects millions of patients in the United States and continues to be an area where improved symptom control and treatment adherence remain important considerations.
Shares of Glenmark Pharmaceuticals closed at ₹2,095.50, down ₹36.20 or 1.70% on the NSE.
